{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:21:29Z","timestamp":1747196489657,"version":"3.40.5"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"This work was supported by Sinovac (Dalian) Vaccine Technology Co., LTD."}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Mumps is an acute infectious disease, which was well controlled in the past, but recently it has resurged in some areas. This study aimed to evaluate the safety profile of the live attenuated mumps vaccine after large-scale vaccination. We conducted an observational, open-label phase 4 trial in Shaanxi, China from October 2020 to March 2021. Eligible participants were freshmen of junior high school who were not above 14 years old. Adverse events following immunization (AEFI) monitoring was carried out by active and passive surveillance. Safety follow-ups were conducted during the study participation. Overall, 10057 subjects were enrolled in the active surveillance analysis. A total of 214 subjects reported adverse reactions with an incidence of 2.13% (214\/10057). Most adverse reactions were grade 1, and the incidence of grade 1 adverse reactions was 1.44% (145\/10057); 0.60% for grade 2 (60\/10057); and 0.09% for grade 3 (9\/10057). The majority of adverse reactions were solicited (1.73%, 174\/10057). Injection-site pain was the most frequently reported local adverse reaction (0.71%, 71\/10057), followed by redness (0.29%, 29\/10057). The most common systemic adverse reactions were nausea (0.19%, 19\/10057) and fever (0.16%, 16\/10057). For passive AEFI surveillance, 57 AEFI cases were reported, with an incidence of 19.28\/100000 (57\/287608). And most AEFI cases were common adverse reactions (66.67%, 38\/57). In total, the live attenuated mumps vaccine evaluated in this trial has a favorable safety profile and can be used for large-scale inoculation.<\/jats:p>","DOI":"10.1371\/journal.pone.0291730","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T17:42:34Z","timestamp":1695318154000},"page":"e0291730","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety analysis of a live attenuated mumps vaccine in healthy adolescents in China: A phase 4, observational, open-label trial"],"prefix":"10.1371","volume":"18","author":[{"given":"Weijun","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ningning","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weining","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiantian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruize","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongli","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3234-2668","authenticated-orcid":true,"given":"Chunfang","family":"Luan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaobai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2023,9,21]]},"reference":[{"issue":"3","key":"pone.0291730.ref001","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.meegid.2004.02.003","article-title":"The molecular epidemiology of mumps virus","volume":"4","author":"K. M\u00fchlemann","year":"2004","journal-title":"Infect Genet Evol"},{"issue":"9616","key":"pone.0291730.ref002","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S0140-6736(08)60419-5","article-title":"Mumps.","volume":"371","author":"A Hviid","year":"2008","journal-title":"Lancet"},{"issue":"5","key":"pone.0291730.ref003","doi-asserted-by":"crossref","first-page":"e1004791","DOI":"10.1371\/journal.ppat.1004791","article-title":"Remembering mumps.","volume":"11","author":"DR Latner","year":"2015","journal-title":"PLoS Pathog"},{"issue":"7","key":"pone.0291730.ref004","first-page":"611","article-title":"Epidemic profile of mumps in China during 2004\u20132013.","volume":"50","author":"QR Su","year":"2016","journal-title":"Chin J Prev Med"},{"issue":"7","key":"pone.0291730.ref005","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/INF.0000000000001182","article-title":"Emerging Mumps Infection","volume":"35","author":"S Rubin","year":"2016","journal-title":"Pediatr Infect Dis J"},{"issue":"22","key":"pone.0291730.ref006","first-page":"629","article-title":"Notice to readers: updated recommendations of the Advisory Committee on Immunization Practices (ACIP) for the control and elimination of mumps.","volume":"55","author":"Centers for Disease Control and Prevention","year":"2006","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"5","key":"pone.0291730.ref007","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.4161\/hv.28334","article-title":"Safety and immunogenicity of a live attenuated mumps vaccine: a phase I clinical trial","volume":"10","author":"Y Liang","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"pone.0291730.ref008","first-page":"356","article-title":"Analysis of epidemic characteristics and viral gene characteristics of Mumps in China from 2018 to 2019","volume":"37","author":"Y Wang","year":"2021","journal-title":"Chinese Journal of Virology"},{"issue":"4","key":"pone.0291730.ref009","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1086\/520028","article-title":"Mumps outbreaks in Canada and the United States: time for new thinking on mumps vaccines","volume":"45","author":"H Peltola","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"11","key":"pone.0291730.ref010","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1086\/591196","article-title":"Mumps outbreaks in vaccinated populations: are available mumps vaccines effective enough to prevent outbreaks?","volume":"47","author":"GH Dayan","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"10","key":"pone.0291730.ref011","doi-asserted-by":"crossref","first-page":"30156","DOI":"10.2807\/1560-7917.ES.2016.21.10.30156","article-title":"Waning immunity against mumps in vaccinated young adults, France 2013.","volume":"21","author":"S Vygen","year":"2016","journal-title":"Euro Surveill."},{"issue":"7","key":"pone.0291730.ref012","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1086\/528993","article-title":"Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up","volume":"197","author":"I Davidkin","year":"2008","journal-title":"J Infect Dis"},{"issue":"433","key":"pone.0291730.ref013","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao5945","article-title":"Vaccine waning and mumps re-emergence in the United States","volume":"10","author":"JA Lewnard","year":"2018","journal-title":"Sci Transl Med"},{"issue":"13","key":"pone.0291730.ref014","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/j.vaccine.2019.02.030","article-title":"Differential durability of immune responses to measles and mumps following MMR vaccination","volume":"37","author":"RB Kennedy","year":"2019","journal-title":"Vaccine"},{"issue":"12","key":"pone.0291730.ref015","first-page":"1105","article-title":"Sequencing and analysis of mumps virus vaccine strain S79 Genome","volume":"30","author":"J Zhang","year":"2010","journal-title":"Chin J Microbiol Immunol"},{"issue":"2","key":"pone.0291730.ref016","first-page":"150","article-title":"Sequence research on S79 strain of mumps virus during the successive passaging","volume":"13","author":"WZ Yang","year":"2007","journal-title":"Chinese Journal of Vaccines and Immunization"},{"key":"pone.0291730.ref017","first-page":"28","article-title":"The role of the china experts advisory committee on immunization program","volume":"1","author":"J Zheng","year":"2010","journal-title":"Vaccine"},{"issue":"5","key":"pone.0291730.ref018","first-page":"441","article-title":"Epidemiological characteristics of mumps in mainland China from 2004 to 2018 and key population for prevention and control.","volume":"21","author":"RJ Jiang","year":"2019","journal-title":"Chin J Contemp Pediatr"},{"issue":"3","key":"pone.0291730.ref019","first-page":"242","article-title":"Comparison of mumps incidence in areas of China with different immunization strategies, 2012\u20132019","volume":"27","author":"H Yang","year":"2021","journal-title":"Chinese Journal of Vaccines and Immunization"},{"issue":"7","key":"pone.0291730.ref020","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1080\/21645515.2019.1708162","article-title":"High risk of mumps infection in children who received one dose of mumps-containing vaccine: waning immunity to mumps in children aged 2\u20135 years from kindergartens in Jiangsu Province, China.","volume":"16","author":"X Sun","year":"2020","journal-title":"Hum Vaccin Immunother."},{"volume-title":"Guidelines for grading standards of adverse events in clinical trials of preventive vaccines","year":"2019","author":"National Medical Products Administration","key":"pone.0291730.ref021"},{"issue":"32","key":"pone.0291730.ref022","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1016\/j.vaccine.2015.04.060","article-title":"Surveillance of adverse events following immunization in China: Past, present, and future","volume":"33","author":"DW Liu","year":"2015","journal-title":"Vaccine"},{"volume-title":"National guideline for the surveillance of adverse events following immunization","year":"2010","author":"China Ministry of Health, Food and Drug Administration of China","key":"pone.0291730.ref023"},{"issue":"5","key":"pone.0291730.ref024","first-page":"535","article-title":"Immunogenicity and safety of a booster dose of domestic monovalent mumps attenuated live vaccine","volume":"24","author":"XS Zhang","year":"2018","journal-title":"Chinese Journal of Vaccines and Immunization"},{"issue":"5","key":"pone.0291730.ref025","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.4161\/hv.28334","article-title":"Safety and immunogenicity of a live attenuated mumps vaccine: a phase I clinical trial","volume":"10","author":"Y Liang","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"pone.0291730.ref026","first-page":"1086","article-title":"Immunogenicity and safety of a boost dose of measles, mumps, and rubella combined vaccine for 4\u20136 years old children.","volume":"42","author":"YH Xiao","year":"2021","journal-title":"Chin J Epidemiol."},{"issue":"2","key":"pone.0291730.ref027","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1586\/14760584.2014.866895","article-title":"Active surveillance for adverse events following immunization.","volume":"13","author":"NW Crawford","year":"2014","journal-title":"Expert Rev Vaccines"},{"issue":"8","key":"pone.0291730.ref028","article-title":"Safety of measles, rubella and mumps vaccines in adults: a prospective cohort study.","volume":"28","author":"N Ami","year":"2021","journal-title":"J Travel Med."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0291730","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T17:42:54Z","timestamp":1695318174000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0291730"}},"subtitle":[],"editor":[{"given":"Omar Enzo","family":"Santangelo","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,9,21]]},"references-count":28,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0291730","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2023,9,21]]}}}